85% of the human proteome remains undruggable – we are seeking to change that.

We are developing a pipeline of truly novel small molecule inhibitors targeting cancers and other diseases with high unmet medical need.

We are developing a pipeline of truly novel small molecule inhibitors targeting cancers and other diseases with high unmet medical need.

TECHNOLOGY

We have created DragonFold, our end-to-end algorithm that predicts protein/ligand co-folding to discover novel transformational medicines for hard-to-drug targets.

OUR APPROACH

We apply proprietary expertise to the challenge of protein/ligand co-folding to discover and develop a new wave of novel medicines in cancer and other indications. Our DragonFold technology, inspired by the breakthroughs of our co-founder and Wiley- Prize winner David Baker, is the first rapid, accurate protein/ligand co-folding algorithm.

We use our state-of-the-art lab facilities to validate our AI-derived medicines in an integrative loop, striving to bring them to patients as fast as possible.